MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
- Resource Type
- Article
- Authors
- Arena, Sabrina; Siravegna, Giulia; Mussolin, Benedetta; Kearns, Jeffrey D.; Wolf, Beni B.; Misale, Sandra; Lazzari, Luca; Bertotti, Andrea; Trusolino, Livio; Adjei, Alex A.; Montagut, Clara; Di Nicolantonio, Federica; Nering, Rachel; Bardelli, Alberto
- Source
- Science Translational Medicine; 2/3/2016, Vol. 8 Issue 324, p1-10, 10p
- Subject
- COLON cancer
EPIDERMAL growth factor receptors
EXTRACELLULAR space
CETUXIMAB
IMMUNOGLOBULINS
CELL growth
- Language
- ISSN
- 19466234
The article discusses the study on the sensitivity of anti-epidermal growth factor receptor (EGFR) extracellular domain (ECD)-resistant variants of colorectal cancers to EGFR blockade by the oligoclonal antibody MM-151. MM-151 reportedly binds various regions of EGFR ECD which inhibit EGFT signalling and cell growth. The results revealed that MM-151 can overcome resistance to cetuximab and panitumumab in colon cancer.